Market News AIOpen the app

SYRE stock news · Spyre Therapeutics, Inc.

Stories about Spyre Therapeutics, Inc. (SYRE) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for SYRE

Follow Spyre Therapeutics, Inc. (SYRE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SYRE
Free on the App Store and Google Play, or on the web.
  1. Nov 3, 2026, 4:06 PM ET · Market

    Spyre Therapeutics shared its financial results for the third quarter of 2026.

    Neutral

    Spyre filed a release covering the quarter ended September 30, 2026, but the supplied text gives no figures. It does not show a change in the company's outlook.

  2. Oct 7, 2026, 8:05 AM ET · Market

    Spyre Therapeutics, Inc. has signed a big deal to sell 4,117,648 shares for $85 each.

    Neutral

    Spyre Therapeutics plans to sell shares to fund drug research and company needs. The cash supports development, but new shares leave current owners with a smaller piece, so the report does not clearly favor either side.

  3. Sep 8, 2026, 8:05 AM ET · Market

    Spyre Therapeutics shares good news about their drug SPY003 after 12 weeks of testing.

    Good for SYRE

    Spyre Therapeutics, Inc. disclosed positive 12-week induction topline results from Part A of the Phase 2 SKYLINE trial for SPY003, indicating significant efficacy in treating moderately-to-severely active ulcerative colitis.